Investor call, page-22

Daniel Kenny, chief executive officer, commented:

"After a lengthy and complex review it is clear that the company is now well on its way to obtaining the CE Mark this year.

"I am pleased with the progress that the OncoSil team has made over the past 12 months in securing the IDE from the FDA, and the on-boarding of top tier recruitment sites in Australia, UK and the US.

"OncoSil is well positioned to collect the supplemental data quickly and to finalise our post marketing follow up program to secure the CE Mark in 2017."

The CE Mark review for the Primary Liver indication (HCC) is ongoing.